FDA Updates Yaz Labels

Report this content

Earlier last week, the U.S. Food and Drug Administration (FDA) announced that it will update the drug labels of birth control pills containing drospirene- including Yaz, Yasmin, Ocella, and Gianvi.

Drospirene is a synthetic version of the female hormone, progesterone, or progestin.

The FDA reviewed recent studies and concluded that these types of birth controls may be linked to a higher risk of blood clots compared to other progestin-containing pills. The agency will add this information to the birth control labels.

The labels will warn that some epidemiologic studies reported as high as a three-fold increased risk of blood clots for products containing drospirene when compared to products containing levonorgesterel or other products, according to an FDA press release. The labels will also include a summary of previously released results of an FDA-funded study of the blood clot risks.

If you or a loved one has been harmed by a dangerous birth control such as Yaz, Yazmin or Ocella, contact Sokolove Law for a free legal consultation. A dangerous drug lawyer may be able to help you.

Tags:

Quick facts

For legal help, call (877) 490-6520
Tweet this